On October 5, 2021 Orion reported that it will publish Interim Report for January–September 2021 on Wednesday, 20 October 2021 at approximately 12.00 noon EEST (Press release, Orion , OCT 5, 2021, View Source [SID1234590835]). The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast and conference call

A webcast and a conference call for analysts, investors and media will be held on Wednesday, 20 October 2021 at 13.30 EEST. The event will be held only online and by conference call.

A link to the live webcast will be available on Orion’s website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

On October 5, 2021 NovoCodex Pharma reported positive interim data from a China trial of its lead drug in patients with HER2+ metastatic gastric / gastroesophageal junction (GEJ) cancer(Press release, NovoCodex Biopharmaceuticals, OCT 5, 2021, View Source [SID1234590815]). ARX788 is an antibody-drug conjugate composed of an EGFR antibody targeting EGFR2 and HER2, joined to a apoptosis molecule. The candidate showed a tolerable safety profile and promising efficacy data. NovoCodex acquired China rights to ARX788 from Ambrx, a San Diego biotech. NovoCodex is a majority owned subsidiary of Zhejiang Medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 5, 2021 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Harpoon Therapeutics, OCT 5, 2021, View Source [SID1234590836]). The meeting will be held virtually and in person in Washington, D.C. from November 10-14, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract details:

Title: TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation
Abstract #: 867
Author: Kathryn S. Kwant, Ph.D., et al.
Session Category: Novel Single-Agent Immunotherapies
Poster Presentation Date and Time: November 12, 7 a.m. – 8:30 p.m. ET

The full abstract will be released on November 9, 2021 at 8 a.m. ET and the poster will be available on Harpoon’s website following the presentation.

For more details about the SITC (Free SITC Whitepaper) Virtual Annual Meeting please visit: View Source

On October 5, 2021 Himalaya Therapeutics of Shanghai has submitted four INDs in China for two Conditionally Active Biologics, each one aimed at two solid tumor cancer indications(Press release, Himalaya Therapeutics, OCT 5, 2021, View Source [SID1234590817]). The company describes itself as a global clinical-stage biotech developing drugs that have more selective targeting for greater safety and efficacy. It also works to be more cost-efficient with highly predictable manufacturing compared to traditional antibodies. Himalaya, a majority owned subsidiary of San Diego’s BioAtla, develops BioAtla’s products in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 5, 2021 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 5th Annual NASH Investor Conference, being held virtually on October 12, 2021 (Press release, CohBar, OCT 5, 2021, View Source [SID1234590837]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 5th Annual NASH Investor Conference
Tuesday, October 12, 2021 at 12:00pm ET
Webcast: The presentation may be accessed via webcast at the scheduled time, or following the presentation, using the following link: View Source
A replay of the webcast will be available in the events section of the CohBar website for two weeks following the presentation.